ATE335511T1 - Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg - Google Patents

Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg

Info

Publication number
ATE335511T1
ATE335511T1 AT98944501T AT98944501T ATE335511T1 AT E335511 T1 ATE335511 T1 AT E335511T1 AT 98944501 T AT98944501 T AT 98944501T AT 98944501 T AT98944501 T AT 98944501T AT E335511 T1 ATE335511 T1 AT E335511T1
Authority
AT
Austria
Prior art keywords
alternative pathway
complement activation
activation via
inhibiting complement
inhibiting
Prior art date
Application number
AT98944501T
Other languages
English (en)
Inventor
Rekha Gupta-Bansal
Kurt R Brunden
James B Parent
Original Assignee
Amgen Fremont Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Fremont Inc filed Critical Amgen Fremont Inc
Application granted granted Critical
Publication of ATE335511T1 publication Critical patent/ATE335511T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • External Artificial Organs (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cereal-Derived Products (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT98944501T 1997-08-26 1998-08-24 Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg ATE335511T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91834997A 1997-08-26 1997-08-26

Publications (1)

Publication Number Publication Date
ATE335511T1 true ATE335511T1 (de) 2006-09-15

Family

ID=25440234

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98944501T ATE335511T1 (de) 1997-08-26 1998-08-24 Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg

Country Status (13)

Country Link
US (3) US6333034B1 (de)
EP (1) EP1007092B1 (de)
JP (1) JP2001513576A (de)
AT (1) ATE335511T1 (de)
AU (1) AU756490B2 (de)
CA (1) CA2302317A1 (de)
DE (1) DE69835524T2 (de)
DK (1) DK1007092T3 (de)
ES (1) ES2270530T3 (de)
NO (1) NO20000935L (de)
NZ (1) NZ503033A (de)
PT (1) PT1007092E (de)
WO (1) WO1999010009A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641571B2 (en) * 2000-01-05 2003-11-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery
ATE449791T1 (de) 2000-10-10 2009-12-15 Genentech Inc Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
EP1416962A4 (de) * 2001-07-26 2006-05-24 Alexion Pharma Inc Verfahren zur verbesserung der kognitiven funktion
ES2198216B1 (es) * 2002-07-02 2005-04-16 Juan Carlos Instituto Cientifico Y Tecnologico De Navarra, S.A.(67%). Medio de cultivo de celulas madre-progenitoras autologas humanas y sus aplicaciones.
EP2305813A3 (de) * 2002-11-14 2012-03-28 Dharmacon, Inc. Funktionale und hyperfunktionale siRNA
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20070123466A1 (en) * 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
US7959919B2 (en) * 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
BRPI0506629A (pt) * 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
EP1737487B1 (de) * 2004-03-30 2016-05-25 Canadian Blood Services Verfahren zur behandlung von autoimmunkrankheiten mit antikörpern
BRPI0401765C1 (pt) * 2004-05-17 2011-03-15 Hy Biotecnologica Ltda método de enriquecimento de espermatozoides de mamìferos portadores de cromossomo x ou de cromossomo y
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CN103505728A (zh) * 2005-05-26 2014-01-15 科罗拉多大学评议会法人机构 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
DK2500030T4 (en) * 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
CN106084055A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
WO2008140653A2 (en) * 2007-03-14 2008-11-20 Taligen Therapeutics, Inc. Humaneered anti-factor b antibody
US9745367B2 (en) * 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
CN101932337A (zh) * 2007-06-11 2010-12-29 宾夕法尼亚大学董事会 替代途径的血清灭菌蛋白调节及其应用
US8981060B2 (en) 2007-08-27 2015-03-17 Novelmed Therapuetics, Inc. Method of inhibiting complement activation with factor Bb specific antibodies
US10131706B2 (en) 2007-08-27 2018-11-20 Novelmed Therapeutics, Inc. Anti-factor Bb antibodies
DK2262831T3 (en) 2008-03-03 2015-04-27 Novelmed Therapeutics Inc ANTI-Properdin ANTIBODIES
US20140127204A1 (en) 2010-09-03 2014-05-08 Novelmed Therapeutics, Inc. Anti-properdin antibodies
US8664362B2 (en) 2008-03-03 2014-03-04 NovelMed Therapeutics Humanized and chimeric anti-properdin antibodies
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2010030789A1 (en) * 2008-09-10 2010-03-18 Novelmed Therapeutics, Inc. Device and method for inhibiting complement activation
WO2010057084A1 (en) * 2008-11-14 2010-05-20 Novelmed Therapeutics, Inc. Method of treating ischemia reperfusion injury
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
EP2544694B1 (de) * 2010-03-02 2018-10-31 Novelmed Therapeutics, Inc. Verfahren zur hemmung von durch alternative pfade vermittelten störungen mit antikörpern gegen properdin zur hemmung von c5-interaktionen mit properdin
EP2545075B1 (de) * 2010-03-10 2020-07-01 NovelMed Therapeutics, Inc. Humanisierte und chimäre antikörper gegen properdin
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
CA2840270C (en) 2011-06-22 2023-09-26 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
JP6293659B2 (ja) 2011-07-01 2018-03-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗プロペルジン抗体およびその使用
SG10201703249PA (en) 2011-12-21 2017-05-30 Novartis Ag Compositions and methods for antibodies targeting factor p
AU2013243574B2 (en) * 2012-04-03 2017-12-07 Novelmed Therapeutics, Inc Humanized and chimeric anti-factor C3 antibodies and uses thereof
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
US9926366B2 (en) 2012-10-04 2018-03-27 Novelmed Therapeutics, Inc. Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies
ES2514165B1 (es) * 2013-03-27 2015-09-09 Consejo Superior De Investigaciones Científicas (Csic) Anticuerpo anti-factor b, composición farmacéutica útil para el tratamiento de enfermedades del complemento y sus aplicaciones
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
TW201730211A (zh) 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
EP3405577B8 (de) 2016-01-20 2023-02-15 396419 B.C. Ltd. Zusammensetzungen und verfahren zur hemmung des faktors d
EP3275897A1 (de) 2016-07-27 2018-01-31 Biotest AG Verfahren zur herstellung von immunoglobulinzusammensetzungen
EP3526248A4 (de) 2016-10-17 2020-07-08 Musc Foundation for Research Development Zusammensetzungen und verfahren zur behandlung von läsionen des zentralnervensystems
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
MX2021006930A (es) 2018-12-11 2021-11-17 Q32 Bio Inc Construcciones de proteínas de fusión para enfermedades asociadas al complemento.
US11981727B2 (en) 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642284A (en) * 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation
US5434075A (en) * 1992-03-20 1995-07-18 Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
AU2191795A (en) 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation

Also Published As

Publication number Publication date
US20020015701A1 (en) 2002-02-07
WO1999010009A1 (en) 1999-03-04
US6333034B1 (en) 2001-12-25
DE69835524D1 (de) 2006-09-21
NO20000935L (no) 2000-04-18
US20030198636A1 (en) 2003-10-23
NZ503033A (en) 2003-01-31
PT1007092E (pt) 2006-12-29
EP1007092B1 (de) 2006-08-09
DK1007092T3 (da) 2006-10-02
ES2270530T3 (es) 2007-04-01
DE69835524T2 (de) 2007-04-05
CA2302317A1 (en) 1999-03-04
EP1007092A1 (de) 2000-06-14
NO20000935D0 (no) 2000-02-25
AU9203398A (en) 1999-03-16
AU756490B2 (en) 2003-01-16
JP2001513576A (ja) 2001-09-04

Similar Documents

Publication Publication Date Title
DE69835524D1 (de) Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg
DE69818304D1 (de) Verfahren zur reduktion von oxiranyl-epothilonen zu olefinischen epothilonen
DE69418714D1 (de) Verfahren zur kryptographischer authentifizierung übertragener nachrichten unter verwendung von pseudo-zufallszahlen
DE69613384D1 (de) Verfahren zur hydrocyanierung von organischen, ethylenisch ungesättigten verbindungen
DE59809789D1 (de) Verfahren zur Herstellung von Propen
DE69200286D1 (de) Verfahren zur Auswertung des Abnutzungszustandes von Erzeugnissen.
DE69018178D1 (de) Verfahren zur Herstellung von Disilan.
DE58903736D1 (de) Verfahren zur behandlung von biomassen, z.b. klaerschlaemmen, guelle, usw.
DE59103454D1 (de) Verfahren zur Herstellung von feinteiligen, wasserlöslichen Polymerisaten.
ATE291567T1 (de) Verfahren zur herstellung von nitroxymethylphenylestern von aspirinderivaten
DE69020172D1 (de) Verfahren zur Herstellung von epsilon-Caprolactam.
EP0666650A3 (de) Verfahren zur schnellen Decodierung der Ausgangssignale von Sigma Delta Modulatoren.
DE69934948D1 (de) Verfahren zur cooxidation von organischen verbindungen
ATE268996T1 (de) Verbessertes formverfahren für konfektprodukte
DE60124289D1 (de) Verfahren zur herstellung von 21-hydroxy-6,19-oxidoprogesteron (21oh-6op)
ATE178410T1 (de) Verfahren zur hochempfindlichen dosierung von herztroponin - i
AU1278801A (en) Method for generating information related to the molecular structure of a biomolecule
EA199900741A1 (ru) Способ получения эпросартана
DE59702009D1 (de) Verfahren zur herstellung von 1,4,7,10-tetraazacyclododecan und dessen derivaten
ATE213782T1 (de) Verfahren zur biotransformation von colchicinoid- verbindungen in die entsprechenden 3- glycosylderivate
EA199900740A1 (ru) Способ получения эпросартана (варианты)
ATE428116T1 (de) Verfahren zur identifizierung wahrend der apoptose modifizierter proteine
EP0614853A3 (de) Methode zur Herstellung von Beta-Zeolith.
DE59807664D1 (de) Verfahren zur herstellung von 3-cyano-2,4-dihalogen-5-fluor-benzoesäuren
EP0578016A3 (de) Enzymatisches Verfahren zur Trennung racemischer Gemische von delta-Valerolactonen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1007092

Country of ref document: EP

REN Ceased due to non-payment of the annual fee